Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors

doi:10.3748/wjg.v28.i17.1768

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 17

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4202)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series.

Item

Count

PDF

273

WORD

118

HTML

2455

Figures (1-4)

279

Sum=3125

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

182

Download

232

Sum=414

Publishing Process of This Article

Item

Count

Browse

279

Download

384

Sum=663

May 7, 2022 (publication date) through May 16, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. May 7, 2022; 28(17): 1768-1780
Published online May 7, 2022. doi: 10.3748/wjg.v28.i17.1768

Full Size Figure Download Figure

Figure 3 73 year old female with well-differentiated neuroendocrine tumor (Ki-67 = 6%) and liver metastases with an unknown primary. A: ⁶⁸Ga DOTATATE positron emission tomography (PET)/computed tomography (CT) fusion and whole-body PET projection confirms multifocal hepatic metastases SUVmax 34.4 with an area of focal decreased DOTATATE avidity (arrow); B: Fluorodeoxyglucose (FDG) PET/CT fusion and whole-body PET shows mismatched focal intense increased FDG uptake SUVmax 9.1 (arrow), suggestive of heterogeneous tumor phenotype with areas of dedifferentiation.

Citation: Grey N, Silosky M, Lieu CH, Chin BB. Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors. World J Gastroenterol 2022; 28(17): 1768-1780
URL: https://www.wjgnet.com/1007-9327/full/v28/i17/1768.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i17.1768